Slow Release of an LHRH Analog to Reduce Serum Testosterone

TL;DRAbstract

During the last several decades, research into neuroendocrine control by LHRH and other hypothalamic hormones has been an area of high activity. Since Schally and Guillemin’s Nobel Prize winning work of the early 1970s, the isolation, determination of structure, and synthesis of hypothalamic peptide hormones, as well as the synthesis of their analogs, have revealed radically new approaches to diagnosis and treatment of endocrine and nonendocrine disorders (1–10). Clinical applications of the hypothalamic hormones include: differentiation between hypothalamic and pituitary lesion, stimulation of fertility, birth control, and treatment of precocious puberty, endometriosis, cryptochidism, diabetes mellitus, acromegaly, and acute pancreatitis. The uses of analogs of hypothalamic hormones for hormone-sensitive tumors is relatively more recent, but of major current clinical value and significance, as evidenced by the quick transfer of basic research results to FDA approvals. LHRH agonist ana

Chat with Paper

AI Agents for this Paper